Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1819931 | 0.85 | NOTUM (0.53) | NOTUMHTTKMT2AKDM4EPOLQ | |
| SCHEMBL1824173 | 0.83 | NOTUM (0.51) | NOTUMHTTKMT2AKDM4EPOLQ | |
| SCHEMBL1820289 | 0.81 | NOTUM (0.49) | NOTUMHTTKMT2AKDM4EPOLQ | |
| SCHEMBL1820246 | 0.77 | DRD4 (0.48) | KMT2AKDM4EPOLQPYGLPOLB | |
| SCHEMBL3884249 | 0.77 | NOTUM (0.56) | NOTUMHTTKMT2AKDM4EPOLQ | |
| SCHEMBL1819056 | 0.76 | KMT2A (0.51) | HTTKMT2APOLQPOLBTSHR | |
| SCHEMBL6164413 | 0.75 | NOTUM (0.58) | NOTUMHTTKMT2AKDM4EPOLQ | |
| SCHEMBL25629360 | 0.75 | NOTUM (0.58) | NOTUMHTTKMT2APOLQKCNA5 | |
| SCHEMBL16353843 | 0.75 | NOTUM (0.54) | NOTUMHTTPOLQTRPV1PYGL | |
| SCHEMBL965251 | 0.73 | NOTUM (0.51) | NOTUMHTTKMT2AKDM4EPOLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269213-A1 | 8-Hydroxyquinoline compounds and methods thereof | MMP8, MMP26, MMP9 | NOTUM 3462/4885HTT 334/4885KMT2A 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.